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January 2006200 Zarinsthe aneurysm wall to remain intact, and so the absence of rupture
in EVAR patients, particularly those with small aneurysms, does
not necessarily reflect graft durability or effectiveness. Reports of
loss of the survival advantage conferred by EVAR when compared
with open repair after 1 year of follow-up,4 as well as the present
study’s finding that preoperative aneurysm size was predictive of
rupture after EVAR, do not equate with graft durability. Indeed,
stent fractures have been reported in 71% of for-cause explanted
grafts and in 31% of incidentally explanted grafts.5
Although the need for secondary intervention in 18.28% of
EVAR patients reflects on the effectiveness of the grafts, as well as
on the skill required for their successful deployment, late secondary
intervention in 2.7% of EVAR patients must be assumed to relate
to stent graft failure over time, unless the authors state otherwise.
This is at least as relevant a measure of graft durability as freedom
from rupture. Eighteen aneurysm ruptures were reported in the
EVAR group, and 8 aneurysm-related deaths were reported be-
tween years 1 and 6. A total of 34% of the EVAR group died during
5 years of follow-up, and further information on causes of death
would be of interest. Classification of cause of death as verified,
probable, or indeterminate, as recommended by reporting stan-
dards for aortic EVAR,6 is not provided.
Brian J. Manning, MD
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Cork University Hospital
Cork, Ireland
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Reply
Dr Manning takes issue with our conclusion that endovascular
aneurysm repair (EVAR) is an effective and durable treatment of
infrarenal aortic aneurysms because the conclusion is based on a
low aneurysm rupture and aneurysm-related death rate and a low
surgical conversion rate. However, prevention of aneurysm rup-
ture and death from rupture is precisely why aortic aneurysms are
treated. Therefore, the effectiveness and durability of EVAR in
achieving these objectives must be viewed as the primary outcome
measures. The Lifeline Registry data show that EVAR was effective
in preventing aneurysm rupture in 99% of patients over a 6-year
follow-up period. Similarly, EVAR was effective in preventing
aneurysm-related death in 98% of patients, with no diminution of
effectiveness over the 6-year follow-up period.1 Although avoiding“surgical conversion”—or open surgical repair—is not a primary
objective of aneurysm treatment per se, it is an objective of EVAR.
Thus, the low surgical conversion rate reported by the Lifeline
Registry must be viewed as evidence of the effectiveness and
durability of EVAR in achieving the objective of avoiding open
surgical repair. In this regard, it should be noted that the surveil-
lance strategy for small aneurysms to which Dr Manning refers2
was not entirely effective in preventing aneurysm rupture and
death, because 1% of small aneurysms ruptured each year despite
close surveillance and early treatment, if needed. Furthermore, the
mortality rate for rupture was very high (90%): 11% of all deaths in
the surveillance group were due to aneurysm rupture. Surveillance
also was not a durable strategy in the UK small aneurysm trial,
because 74% of patients in the surveillance group were treated with
open surgery over an 8-year follow-up period.2
With regard to reports of a loss of EVAR’s early survival
advantage over open surgery after 1 year, no information on graft
durability was provided.3 Indeed, the use of all-cause mortality as
the primary end point in these trials may obscure information
related to the long-term durability of each aneurysm treatment
strategy, because most deaths were due to non–aneurysm-related
causes. In the prospective, randomized EVAR-1 trial, the reduc-
tion in the aneurysm-related death rate after EVAR (4%) remained
lower than that after open surgery (7%) at 4 years (P  .04).4
Similarly, there was a persistent low aneurysm-related death rate
after EVAR in the Lifeline Registry (2% at 6 years). The threefold
reduction in perioperative mortality which was demonstrated in
the prospective randomized trials,3,4 along with the reduced mor-
bidity and more rapid recovery after EVAR, is a significant advan-
tage to the patient despite subsequent late death from unrelated
causes.
The Lifeline Registry report was focused on the primary
outcome measures of EVAR as a treatment strategy and not on the
specifics of individual device durability. As Dr Manning indicates,
adverse events and endograft device failures can occur after EVAR.
After 5 years, 22% of patients in the Lifeline Registry had under-
gone a secondary interventional procedure, and 5% had undergone
surgical conversion. Nonetheless, the long-term primary outcome
measures remained stable, with no suggestion of an increasing
aneurysm rupture or aneurysm-related death rate over time, and
open surgical repair had been avoided in 95% of patients. Thus,
EVAR can be viewed as an effective and durable treatment strategy,
within the 6-year time frame of the study, provided that patients
are monitored and secondary treatments are performed when
needed.
Christopher K. Zarins, MD, on behalf of the Lifeline Registry of
EVAR Publications Committee
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